Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity
Copyright © 2019 Endocrine Society..
OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans.
DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined.
RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation.
CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:104 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 104(2019), 11 vom: 01. Nov., Seite 5703-5714 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dollerup, Ole L [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 03.06.2020 Date Revised 04.12.2021 published: Print ClinicalTrials.gov: NCT02303483 Citation Status MEDLINE |
|---|
| doi: |
10.1210/jc.2019-01081 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300007191 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300007191 | ||
| 003 | DE-627 | ||
| 005 | 20231225101603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/jc.2019-01081 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1000.xml |
| 035 | |a (DE-627)NLM300007191 | ||
| 035 | |a (NLM)31390002 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dollerup, Ole L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.06.2020 | ||
| 500 | |a Date Revised 04.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT02303483 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Endocrine Society. | ||
| 520 | |a OBJECTIVE: Augmenting nicotinamide adenine dinucleotide (NAD+) metabolism through dietary provision of NAD+ precursor vitamins translates to improved glucose handling in rodent models of obesity and diabetes. Preclinical evidence suggests that the NAD+/SIRT1 axis may be implicated in modulating important gut-related aspects of glucose regulation. We sought to test whether NAD+ precursor supplementation with nicotinamide riboside (NR) affects β-cell function, α-cell function, and incretin hormone secretion as well as circulating bile acid levels in humans | ||
| 520 | |a DESIGN: A 12-week randomized, double-blind, placebo-controlled, parallel-group trial in 40 males with obesity and insulin resistance allocated to NR at 1000 mg twice daily (n = 20) or placebo (n = 20). Two-hour 75-g oral glucose tolerance tests were performed before and after the intervention, and plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were determined. β-Cell function indices were calculated based on glucose, insulin, and C-peptide measurements. Fasting plasma concentrations of bile acids were determined | ||
| 520 | |a RESULTS: NR supplementation during 12 weeks did not affect fasting or postglucose challenge concentrations of glucose, insulin, C-peptide, glucagon, GLP-1, or GIP, and β-cell function did not respond to the intervention. Additionally, no changes in circulating adipsin or bile acids were observed following NR supplementation | ||
| 520 | |a CONCLUSION: The current study does not provide evidence to support that dietary supplementation with the NAD+ precursor NR serves to impact glucose tolerance, β-cell secretory capacity, α-cell function, and incretin hormone secretion in nondiabetic males with obesity. Moreover, bile acid levels in plasma did not change in response to NR supplementation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a C-Peptide |2 NLM | |
| 650 | 7 | |a Insulin |2 NLM | |
| 650 | 7 | |a Pyridinium Compounds |2 NLM | |
| 650 | 7 | |a nicotinamide-beta-riboside |2 NLM | |
| 650 | 7 | |a 0I8H2M0L7N |2 NLM | |
| 650 | 7 | |a Niacinamide |2 NLM | |
| 650 | 7 | |a 25X51I8RD4 |2 NLM | |
| 650 | 7 | |a Gastric Inhibitory Polypeptide |2 NLM | |
| 650 | 7 | |a 59392-49-3 |2 NLM | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 650 | 7 | |a Glucagon |2 NLM | |
| 650 | 7 | |a 9007-92-5 |2 NLM | |
| 700 | 1 | |a Trammell, Samuel A J |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Bolette |e verfasserin |4 aut | |
| 700 | 1 | |a Holst, Jens J |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a Møller, Niels |e verfasserin |4 aut | |
| 700 | 1 | |a Gillum, Matthew P |e verfasserin |4 aut | |
| 700 | 1 | |a Treebak, Jonas T |e verfasserin |4 aut | |
| 700 | 1 | |a Jessen, Niels |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 104(2019), 11 vom: 01. Nov., Seite 5703-5714 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:104 |g year:2019 |g number:11 |g day:01 |g month:11 |g pages:5703-5714 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/jc.2019-01081 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 104 |j 2019 |e 11 |b 01 |c 11 |h 5703-5714 | ||